🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 11/07/2012 | 54,39 | 54,73 | 52,55 | 52,76 | -2,58% | 4,01% | 1.884.400 |
| 10/07/2012 | 54,58 | 55,23 | 53,99 | 54,16 | +0,04% | 2,27% | 2.017.000 |
| 09/07/2012 | 55,45 | 55,59 | 53,89 | 54,14 | -0,95% | 3,07% | 1.874.100 |
| 06/07/2012 | 55,53 | 55,77 | 54,13 | 54,66 | -1,53% | 2,95% | 1.345.200 |
| 05/07/2012 | 55,51 | 56,03 | 55,31 | 55,51 | +0,09% | 1,30% | 1.647.600 |
| 03/07/2012 | 55,63 | 56,00 | 54,43 | 55,46 | -0,18% | 2,82% | 1.109.900 |
| 02/07/2012 | 56,10 | 56,17 | 54,50 | 55,56 | -0,64% | 2,98% | 2.490.800 |
| 29/06/2012 | 53,24 | 56,50 | 52,29 | 55,92 | +9,26% | 7,91% | 6.203.600 |
| 28/06/2012 | 53,93 | 56,67 | 47,86 | 51,18 | -16,25% | 16,34% | 19.489.900 |
| 27/06/2012 | 60,78 | 61,18 | 59,19 | 61,11 | +2,50% | 3,27% | 1.524.900 |
| 26/06/2012 | 58,80 | 60,00 | 58,43 | 59,62 | +2,04% | 2,67% | 1.364.300 |
| 25/06/2012 | 60,08 | 60,32 | 57,89 | 58,43 | -3,60% | 4,04% | 1.416.100 |
| 22/06/2012 | 57,87 | 60,61 | 57,20 | 60,61 | +5,23% | 5,89% | 3.009.300 |
| 21/06/2012 | 59,19 | 59,37 | 57,39 | 57,60 | -2,62% | 3,35% | 1.267.800 |
| 20/06/2012 | 57,50 | 59,27 | 57,04 | 59,15 | +3,35% | 3,88% | 2.582.600 |
| 19/06/2012 | 58,04 | 58,77 | 56,87 | 57,23 | -0,93% | 3,27% | 1.849.000 |
| 18/06/2012 | 56,27 | 59,25 | 56,26 | 57,77 | +2,18% | 5,31% | 1.750.100 |
| 15/06/2012 | 56,14 | 56,96 | 55,78 | 56,54 | +1,07% | 2,10% | 2.610.200 |
| 14/06/2012 | 55,25 | 56,32 | 54,02 | 55,94 | +0,87% | 4,16% | 1.965.400 |
| 13/06/2012 | 55,98 | 57,12 | 55,10 | 55,46 | -0,88% | 3,61% | 2.040.000 |
| 12/06/2012 | 54,98 | 56,34 | 54,90 | 55,95 | +1,91% | 2,62% | 1.676.400 |
| 11/06/2012 | 56,91 | 57,04 | 54,62 | 54,90 | -3,65% | 4,25% | 3.419.500 |
| 08/06/2012 | 57,10 | 57,75 | 55,46 | 56,98 | +0,37% | 4,01% | 2.740.300 |
| 07/06/2012 | 58,42 | 58,52 | 56,15 | 56,77 | -1,85% | 4,06% | 3.622.100 |
| 06/06/2012 | 59,01 | 59,16 | 57,65 | 57,84 | -1,23% | 2,56% | 2.551.600 |
| 05/06/2012 | 57,60 | 59,52 | 57,50 | 58,56 | +1,49% | 3,51% | 2.534.800 |
| 04/06/2012 | 59,49 | 59,63 | 57,05 | 57,70 | -3,12% | 4,34% | 3.253.000 |
| 01/06/2012 | 59,23 | 60,54 | 58,56 | 59,56 | -0,80% | 3,34% | 3.820.300 |
| 31/05/2012 | 59,71 | 60,55 | 59,59 | 60,04 | -0,23% | 1,61% | 4.083.300 |
| 30/05/2012 | 57,72 | 61,45 | 56,48 | 60,18 | +4,12% | 8,61% | 10.176.700 |